Therapeutic options for adult T-cell leukemia/lymphoma

Current Oncology Reports

Volumn 15, Issue 5, 2013, Pages 457-464

  Marçais, Ambroise ^a,b   Suarez, Felipe ^a,b   Sibon, David ^a,b   Frenzel, Laurent ^a,b   Hermine, Olivier ^a,b   Bazarbachi, Ali ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b IMAGINE INSTITUTE   (France)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Adult T cell leukemia lymphoma; Arsenic; Chemotherapy; Human T cell lymphotropic virus 1; Interferon; Zidovudine

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIVIRUS AGENT; ARSENIC TRIOXIDE; BASILIXIMAB; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MOGAMULIZUMAB; PEGINTERFERON ALPHA; PENTOSTATIN; PREDNISOLONE; PROCARBAZINE; RANIMUSTINE; ROMIDEPSIN; UNINDEXED DRUG; VALACICLOVIR; VALPROIC ACID; VINCRISTINE; VINDESINE; VORINOSTAT; ZIDOVUDINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; HODGKIN DISEASE; HUMAN; HYPERCALCEMIA; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; SURVIVAL TIME; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT INDICATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MOLECULAR TARGETED THERAPY; PROGNOSIS;

EID: 84884592600     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0332-6     Document Type: Article

References (43)

1. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-37.
2. • Tsukasaki K, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453-9. This paper describes consensus diagnosis criteria and Treatment of HTLV-1 related lymphoproliferation.
3. Marçais A, Suarez F, Sibon D, Bazarbachi A, Hermine O. Clinical trials of adult T-cell leukaemia/lymphoma treatment. Leuk Res Treat. 2012;2012:932175.
4. Takasaki Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:433.
5. Shimoyama M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol. 1988;6:1088-97.
6. Tsukasaki K, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77:164-70.
7. Yamada Y, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375-82.
8. Tsukasaki K, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458-64.
9. Hishizawa M, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369.
10. Uike N, Tanosaki R, Utsunomiya A, Choi I, Okamura J. Can allo-SCT with RIC cure ATLL? long-term survivors with excellent PS and with heterogenous HTLV-1 proviral load level. Retrovirology. 2011;8:A33.
11. Itonaga H, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood. 2013;121:219-25.
12. Kanda J, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141-8.
13. Gill PS, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744-8.
14. Hermine O, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749-51.
15. Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S186-90.
16. Hermine O, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3:276-82.
17. White JD, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2001;40:287-94.
18. •• Bazarbachi A, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177-83. This paper reports the efficacy of the combination of anti-retroviral therapy in all subtypes of ATLL except lymphoma subtype. Data are based on a retrospective analysis of a large series of patients from France, UK and US.
19. Nasr R, et al. Controversies in targeted therapy of adult T cell leukemia/lymphoma: om target or off target effects? Viruses. 2011;3:750-69.
20. Datta A, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006;108:1021-9.
21. Hodson A, et al. Addition of anti-viral therapy to chemotherapy improves overall survival in acute and lymphomatous adult T-cell leukaemia/lymphoma (ATLL). Blood. 2010;116(21):Abstr 3961.
22. Bazarbachi A, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278-83.
23. El-Sabban ME, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000;96:2849-55.
24. Nasr R, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 2003;101:4576-82.
25. El Hajj H, et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med. 2010;207:2785-92.
26. Kchour G, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009;113:6528-32.
27. Suarez F, et al. Arsenic trioxyde in the treatment of HTLV1 associated ATLL. Retrovirology. 2011;8:A59.
28. Waldmann TA, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701-12.
29. Waldmann TA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-75.
30. Moura I, et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Retrovirology. 2011;8:A60.
31. Utsunomiya A, et al. Promising results of an anti-CCR4 antibody, KW-0761, for relapsed adult T-cell leukemia-lymphoma (ATL). Retrovirology. 2011;8:A40.
32. Ishida T, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837-42.
33. Olsen EA, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-15.
34. Whittaker SJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485-91.
35. Piekarz RL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827.
36. Coiffier B, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631-6.
37. Ramos J, et al. Targeting HTLV-I latency in adult T-cell leukemia/lymphoma. Retrovirology. 2011;8:A48.
38. Afonso PV, et al. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood. 2010;116:3802-8.
39. Dearden CE, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721-6.
40. Mone A, et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-a-refractory adult T-cell leukemia. Blood. 2005;106:3380-2.
41. Ravandi F, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009;27:5425-30.
42. Maeda N, Muta H, Oflazoglu E, Yoshikai Y. Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo. Cancer Sci. 2010;101:224-30.
43. Flaman JM, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A. 1995;92:3963-7.